BioSpace News Archive

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

Autolus Therapeutics plc today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia (ALL) patients.

March 31, 2022
·
5 min read
Business

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months and year ended December 31, 2021 and provided a business update.

March 31, 2022
·
13 min read
Business

Sharecare announces fourth quarter and full year 2021 financial results and operational highlights

Sharecare today announced financial results for the quarter and year ended December 31, 2021.

March 31, 2022
·
19 min read
Drug Development

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer.

March 31, 2022
·
7 min read
Business

South Rampart Pharma Appoints Robert Dickey, MBA, as Chief Financial Officer

South Rampart Pharma today announced the appointment of Robert Dickey, MBA, as its Chief Financial Officer.

March 31, 2022
·
3 min read
Drug Development

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors.

March 31, 2022
·
4 min read
Drug Development

InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

InflaRx N.V. announced today that the Phase III part of the Phase II/III PANAMO study with mechanically ventilated COVID-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9% (vilobelimab 31.7% versus placebo 41.6%, p=0.094).

March 31, 2022
·
9 min read
Business

Abeona Therapeutics Announces Strategy Update and 2021 Financial Results

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today provided a business and strategy update and reported 2021 financial results.

March 31, 2022
·
11 min read
Global Heart Pump Device Market Trends, Business Opportunity and Competitive Analysis Study

Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices.

March 31, 2022
·
7 min read
Renal Cell Carcinoma Market: Rising incidence of renal cell carcinoma to drive the market

Albany NY, United States: Renal cell carcinoma, also known as adenocarcinoma, refers to the cancer of kidneys in which malignant cells are found in the renal tubules.

March 31, 2022
·
6 min read